APA

Christopher R., Covington P., Davenport M., Fleck P., Mekki Q. A., Wann E. R. & Karim A. (20081001). Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. : Clinical therapeutics.

Chicago

Christopher Ronald, Covington Paul, Davenport Michael, Fleck Penny, Mekki Qais A, Wann Elisabeth R and Karim Aziz. 20081001. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. : Clinical therapeutics.

Harvard

Christopher R., Covington P., Davenport M., Fleck P., Mekki Q. A., Wann E. R. and Karim A. (20081001). Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. : Clinical therapeutics.

MLA

Christopher Ronald, Covington Paul, Davenport Michael, Fleck Penny, Mekki Qais A, Wann Elisabeth R and Karim Aziz. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. : Clinical therapeutics. 20081001.